Voyager Acquisition Corp. - Units (1 Ord Class A & 1/2 War)
VACHU - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$475.46M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $475.46 Million |
|---|---|
| Enterprise Value | $475.42 Million |
| Earnings per Share | $- |
| Beta | 0.35 |
| Outstanding Shares | - |
Return
| Return on Equity | -43.92% |
|---|---|
| Return on Assets | 2.47% |
| Return on Invested Capital | 137.62% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -143.75 |
| Enterprise Value to Net Income | 70 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Last Earnings Call
Report Date
May 13, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.02%▼ 0.96% |
|---|---|
| Total Invested | $27,837▼ 98.97% |
| Investors Holding | 2▼ 2.00% |
About Voyager Acquisition Corp.
8 employees
CEO: Christoph Antz
Veraxa Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a ...